Volociximab

Drug Profile

Volociximab

Alternative Names: Anti-α5β1 integrin antibody; Eos 200-4; M 200

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PDL BioPharma
  • Developer Abbott Biotherapeutics Corp; Biogen Idec; National Cancer Institute (USA); OphthoTech Corporation; PDL BioPharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Integrin alpha 5 beta 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Intestinal cancer; Non-small cell lung cancer; Peritoneal cancer
  • Discontinued Malignant melanoma; Pancreatic cancer; Renal cell carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in USA (Intravitreous, Injection)
  • 24 Jan 2013 Discontinued - Phase-II for Ovarian cancer (monotherapy, second-line) in USA (IV)
  • 24 Jan 2013 Discontinued - Phase-II for Ovarian cancer (monotherapy, second-line) in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top